What's more, quite a few very well proven adverse prognostic markers, like U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, missing their unfavorable impact in individuals treated with VO. The sole component that remained predictive of a shorter development-free survival With this cohort of patients was TP53 aberrations.112 Ultimately, the alterna